drugset / Trial / NCT00256698

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

NCT00256698

Phase 3 Completed 514 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive women with first relapse of breast cancer.

Timeline

Start
2004-01
Primary completion
2009-04
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulvestrant Small molecule 250 mg Intramuscular
Background Anastrozole Other / unclassified 1 mg Oral

Indications